Grifols S.A (G0FB) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Grifols S.A (G0FB) has a cash flow conversion efficiency ratio of 0.057x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€430.86 Million ≈ $503.73 Million USD) by net assets (€7.60 Billion ≈ $8.89 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Grifols S.A net asset quality index to measure how much of total assets are equity-financed.
Grifols S.A - Cash Flow Conversion Efficiency Trend (2016–2025)
This chart illustrates how Grifols S.A's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check how high is Grifols S.A's earnings quality to evaluate the quality of earnings relative to operating cash generation.
Grifols S.A Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Grifols S.A ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Linamar Corporation
TO:LNR
|
0.040x |
|
Loncin Motor Co Ltd
SHG:603766
|
0.084x |
|
X-Energy, Inc. Class A Common Stock
NASDAQ:XE
|
-0.064x |
|
Indian Railway Catering And Tourism Corporation Limited
NSE:IRCTC
|
0.196x |
|
BBVA Banco Frances SA
BA:BBAR
|
0.203x |
|
ENTAIN PLC UNSP.ADR/1
F:6GI0
|
N/A |
|
Millrose Properties, Inc.
NYSE:MRP
|
0.136x |
|
Beijing Shougang Co Ltd
SHE:000959
|
0.059x |
Annual Cash Flow Conversion Efficiency for Grifols S.A (2016–2025)
The table below shows the annual cash flow conversion efficiency of Grifols S.A from 2016 to 2025. For the full company profile with market capitalisation and key ratios, see Grifols S.A (G0FB) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €7.60 Billion ≈ $8.89 Billion |
€1.05 Billion ≈ $1.22 Billion |
0.138x | +31.40% |
| 2024-12-31 | €8.61 Billion ≈ $10.06 Billion |
€902.00 Million ≈ $1.05 Billion |
0.105x | +260.06% |
| 2023-12-31 | €7.51 Billion ≈ $8.78 Billion |
€218.69 Million ≈ $255.67 Million |
0.029x | +2365.22% |
| 2022-12-31 | €8.46 Billion ≈ $9.89 Billion |
€-10.87 Million ≈ $-12.70 Million |
-0.001x | -101.75% |
| 2021-12-31 | €8.15 Billion ≈ $9.52 Billion |
€596.98 Million ≈ $697.93 Million |
0.073x | -55.65% |
| 2020-12-31 | €6.72 Billion ≈ $7.86 Billion |
€1.11 Billion ≈ $1.30 Billion |
0.165x | +98.81% |
| 2019-12-31 | €6.85 Billion ≈ $8.00 Billion |
€568.93 Million ≈ $665.14 Million |
0.083x | -47.07% |
| 2018-12-31 | €4.70 Billion ≈ $5.49 Billion |
€737.43 Million ≈ $862.13 Million |
0.157x | -32.21% |
| 2017-12-31 | €3.63 Billion ≈ $4.25 Billion |
€841.75 Million ≈ $984.09 Million |
0.232x | +56.07% |
| 2016-12-31 | €3.73 Billion ≈ $4.36 Billion |
€553.28 Million ≈ $646.84 Million |
0.148x | -- |
About Grifols S.A
Grifols, S.A., together with its subsidiaries, engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally. It operates through four segments: Biopharma, Diagnostic, Bio Supplies, and Others. The company offers various hemoderivatives from human plasma for immunology, infectious diseases, hepatology, … Read more